US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LB Pharmaceuticals

24.21

+0.84003.59%

Post-market: 24.210.00000.00%19:31 EDT

Volume:172.32K

Turnover:4.16M

Market Cap:692.54M

PE:-32.57

High:24.60

Open:23.52

Low:22.84

Close:23.37

52wk High:27.55

52wk Low:13.36

Shares:28.61M

Float Shares:19.00M

Volume Ratio:0.55

T/O Rate:0.91%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7433

EPS(LYR):-250.6146

ROE:--

ROA:--

PB:2.23

PE(LYR):-0.10

Loading ...

Overview Company News Filings

Lb Pharmaceuticals Inc - Topline Results Expected in First Quarter of 2028

THOMSON REUTERS

LB Pharmaceuticals Advances LB-102 Into Phase 3, Setting Up a Key Schizophrenia Catalyst for Investors

LB Pharmaceuticals Names Minako Pazdera as General Counsel

Lb Pharmaceuticals Appoints Minako Pazdera, J.d., Ph.d. as General Counsel

THOMSON REUTERS

LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel

LB Pharmaceuticals Grants Equity Awards to New Senior Executives

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Roth Capital Initiates Coverage on LB Pharmaceuticals With Buy Rating

MT Newswires Live

LB Pharmaceuticals initiated with a Buy at Roth Capital

LB Pharmaceuticals, Inc. (LBRX) Receives a New Rating from Roth MKM

Lb Pharmaceuticals Strengthens Leadership Team With Key Appointments in Corporate Affairs and People & Culture

THOMSON REUTERS

Press Release: LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture

Aktis Oncology files for US IPO as biotech listings rebound

LB Pharmaceuticals Grants Chief Commercial Officer Stock Options Valued at $21.36 Per Share

Lb Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Press Release: LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices

Lb Pharmaceuticals Announces Presentation at the Piper Sandler 37TH Annual Healthcare Conference

THOMSON REUTERS

LB Pharmaceuticals Inc. Files Initial Beneficial Ownership Statement for Chief Commercial Officer Kaya Kamlesh Pai Panandiker

LB Pharmaceuticals Expands One Penn Plaza Lease with Additional 4,634 Square Feet

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LBRX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LBRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","market":"US","secType":"STK","nameCN":"LB Pharmaceuticals","latestPrice":24.21,"timestamp":1774468800000,"preClose":23.37,"halted":0,"volume":172319,"hourTrading":{"tag":"盘后","latestPrice":24.21,"preClose":24.21,"latestTime":"19:31 EDT","volume":1466,"amount":35490.9,"timestamp":1774481469145,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.035943517329910135,"floatShares":19000000,"shares":28605700,"eps":-0.743267,"marketStatus":"Not Yet Opened","change":0.84,"latestTime":"03-25 16:00:00 EDT","open":23.52,"high":24.595,"low":22.84,"amount":4164707.949486,"amplitude":0.075096,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.743267,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774512000000},"marketStatusCode":0,"adr":0,"listingDate":1757563200000,"exchange":"NASDAQ","adjPreClose":23.37,"preHourTrading":{"tag":"盘前","latestPrice":23.03,"preClose":23.37,"latestTime":"08:57 EDT","volume":67,"amount":1543.01,"timestamp":1774443438112,"change":-0.34,"changeRate":-0.014549,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":24.21,"preClose":24.21,"latestTime":"19:31 EDT","volume":1466,"amount":35490.9,"timestamp":1774481469145,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.55045},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","floatShares":19000000,"roa":"--","roe":"--","lyrEps":-250.614601,"volumeRatio":0.55045,"shares":28605700,"dividePrice":0,"high":24.595,"amplitude":0.075096,"preClose":23.37,"low":22.84,"week52Low":13.36,"pbRate":"2.23","week52High":27.55,"institutionHeld":0,"latestPrice":24.21,"eps":-0.743267,"divideRate":0,"volume":172319,"delay":0,"ttmEps":-0.743267,"open":23.52,"prevYearClose":22.26,"prevWeekClose":23.53,"prevMonthClose":24.01,"prevQuarterClose":22.26,"fiveDayClose":23.76,"twentyDayClose":25.14,"sixtyDayClose":21.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LBRX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LBRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LBRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1768017600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LBRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LBRX","date":"2026-03-24","current":-32.572413,"percent":0.218045,"low":-35.599566,"twenty":-31.97772,"median":-26.565134,"eighty":-12.239967,"high":-0.410019,"avg":-23.30052,"sd":8.496701,"marketCap":598829744},"quantilePoints":[{"date":"2025-09-12","current":-13.187639,"twenty":-10.632115,"median":-6.798829,"eighty":-2.965543,"marketCap":388099031},{"date":"2025-09-19","current":-12.217088,"twenty":-12.798201,"median":-12.438246,"eighty":-12.070666,"marketCap":359536683},{"date":"2025-09-26","current":-11.40109,"twenty":-12.682283,"median":-12.163705,"eighty":-11.408716,"marketCap":335522685},{"date":"2025-10-03","current":-11.790024,"twenty":-12.394014,"median":-12.03406,"eighty":-11.475827,"marketCap":346968609},{"date":"2025-10-10","current":-11.927294,"twenty":-12.217088,"median":-11.973051,"eighty":-11.471251,"marketCap":351008347},{"date":"2025-10-17","current":-12.506882,"twenty":-12.401641,"median":-12.018808,"eighty":-11.491079,"marketCap":368065019},{"date":"2025-10-24","current":-12.079817,"twenty":-12.247593,"median":-12.026434,"eighty":-11.561239,"marketCap":355496945},{"date":"2025-10-31","current":-12.415368,"twenty":-12.43367,"median":-12.041687,"eighty":-11.652753,"marketCap":365371860},{"date":"2025-11-07","current":-18.511527,"twenty":-12.493155,"median":-12.14464,"eighty":-11.774771,"marketCap":348090759},{"date":"2025-11-14","current":-20.046619,"twenty":-12.715838,"median":-12.201836,"eighty":-11.777822,"marketCap":376956619},{"date":"2025-11-21","current":-21.244034,"twenty":-16.587413,"median":-12.217088,"eighty":-11.811377,"marketCap":399472820},{"date":"2025-11-28","current":-23.934856,"twenty":-18.511527,"median":-12.278098,"eighty":-11.89679,"marketCap":450071024},{"date":"2025-12-05","current":-25.899155,"twenty":-20.625145,"median":-12.354359,"eighty":-11.912042,"marketCap":487007713},{"date":"2025-12-12","current":-27.217658,"twenty":-21.714928,"median":-12.472564,"eighty":-11.927294,"marketCap":511800833},{"date":"2025-12-19","current":-26.50459,"twenty":-23.934856,"median":-12.598395,"eighty":-11.934921,"marketCap":498392309},{"date":"2025-12-26","current":-29.599034,"twenty":-25.317938,"median":-12.735666,"eighty":-11.971526,"marketCap":556580244},{"date":"2026-01-02","current":-29.948841,"twenty":-26.033696,"median":-12.811928,"eighty":-12.003556,"marketCap":563158010},{"date":"2026-01-09","current":-27.984542,"twenty":-26.736001,"median":-17.717835,"eighty":-12.027959,"marketCap":526221321},{"date":"2026-01-16","current":-28.76488,"twenty":-26.943194,"median":-18.511527,"eighty":-12.038636,"marketCap":540894800},{"date":"2026-01-23","current":-31.724783,"twenty":-27.597063,"median":-20.046619,"eighty":-12.056939,"marketCap":596552825},{"date":"2026-01-30","current":-28.482344,"twenty":-28.30475,"median":-20.93459,"eighty":-12.092019,"marketCap":535581989},{"date":"2026-02-06","current":-32.101498,"twenty":-28.673392,"median":-21.418938,"eighty":-12.137776,"marketCap":603636573},{"date":"2026-02-13","current":-32.760749,"twenty":-28.899421,"median":-22.367452,"eighty":-12.188109,"marketCap":616033133},{"date":"2026-02-20","current":-32.558938,"twenty":-29.179266,"median":-23.692682,"eighty":-12.201836,"marketCap":612238268},{"date":"2026-02-27","current":-32.5993,"twenty":-29.599034,"median":-24.876643,"eighty":-12.203361,"marketCap":612997241},{"date":"2026-03-06","current":-31.684421,"twenty":-30.30403,"median":-25.616619,"eighty":-12.210987,"marketCap":595793852},{"date":"2026-03-13","current":-33.554542,"twenty":-31.627914,"median":-25.899155,"eighty":-12.217088,"marketCap":630959603},{"date":"2026-03-20","current":-32.276402,"twenty":-31.988483,"median":-26.370049,"eighty":-12.224714,"marketCap":606925456},{"date":"2026-03-24","current":-31.84587,"twenty":-31.97772,"median":-26.565134,"eighty":-12.239967,"marketCap":598829744}],"updateTime":1774501718734},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LBRX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606248302","title":"Lb Pharmaceuticals Inc - Topline Results Expected in First Quarter of 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2606248302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606248302?lang=en_us&edition=fundamental","pubTime":"2026-01-26 21:00","pubTimestamp":1769432403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nTUA2MQVVK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"gpt_icon":0},{"id":"2605840414","title":"LB Pharmaceuticals Advances LB-102 Into Phase 3, Setting Up a Key Schizophrenia Catalyst for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2605840414","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605840414?lang=en_us&edition=fundamental","pubTime":"2026-01-24 00:33","pubTimestamp":1769185981,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals, Inc. ($LBRX) announced an update on their ongoing clinical study. Study Overview LB Pharmaceuticals, Inc. is launching a late-s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lb-pharmaceuticals-advances-lb-102-into-phase-3-setting-up-a-key-schizophrenia-catalyst-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lb-pharmaceuticals-advances-lb-102-into-phase-3-setting-up-a-key-schizophrenia-catalyst-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4213","BK4211","LBRX","BK4233","LB","ISBC","BK4007"],"gpt_icon":0},{"id":"2605102248","title":"LB Pharmaceuticals Names Minako Pazdera as General Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2605102248","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605102248?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:01","pubTimestamp":1769000469,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Inc. has appointed Dr. Minako Pazdera as General Counsel. Dr. Pazdera brings over 25 years of experience in corporate governance, intellectual property, and strategic transactions. She previously served as General Counsel and Corporate Secretary at Kardigan and Carmot Therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on January 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL2fD717:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014005.SGD","BK4112","NDAQ","SG9999014013.SGD","LU2210149790.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","IE00BKPKM429.USD","LU0314104364.USD","LBRX","LU2095319765.USD","BK4007","SG9999014021.USD"],"gpt_icon":0},{"id":"2605710246","title":"Lb Pharmaceuticals Appoints Minako Pazdera, J.d., Ph.d. as General Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2605710246","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605710246?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:00","pubTimestamp":1769000406,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nTUA1LH1R2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"gpt_icon":0},{"id":"2605107699","title":"LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2605107699","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605107699?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:00","pubTimestamp":1769000400,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan.  21, 2026  (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/21/3222743/0/en/LB-Pharmaceuticals-Appoints-Minako-Pazdera-J-D-Ph-D-as-General-Counsel.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","LB","BK4007","BK4233","LBRX"],"gpt_icon":0},{"id":"2603526551","title":"LB Pharmaceuticals Grants Equity Awards to New Senior Executives","url":"https://stock-news.laohu8.com/highlight/detail?id=2603526551","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603526551?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:05","pubTimestamp":1768251959,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Inc. has granted equity awards to two new executives, Ellen Rose, Senior Vice President of Corporate Affairs, and Lindsay Beaupre, Senior Vice President of People and Culture. Ellen Rose received options to purchase 100,000 shares of common stock, while Lindsay Beaupre received options for 75,000 shares. The options have a ten-year term and an exercise price of $20.73 per share, reflecting the closing price on the grant date. The options vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting monthly over the following three years.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief v","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLbDm04g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4112","LU2095319765.USD","LU2210149790.SGD","LU2210150020.SGD","IE00BKPKM429.USD","LU0314104364.USD","LBRX","SG9999014005.SGD","BK4585","SG9999014013.SGD","BK4588","SG9999014021.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","NDAQ","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2603576526","title":"LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603576526","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603576526?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:05","pubTimestamp":1768251900,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan.  12, 2026  (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Ellen Rose, the new Senior Vice Presi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3217344/0/en/LB-Pharmaceuticals-Reports-Inducement-Grant-to-New-Employee-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX","LB","BK4213","BK4233"],"gpt_icon":0},{"id":"2602872373","title":"Roth Capital Initiates Coverage on LB Pharmaceuticals With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2602872373","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602872373?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:15","pubTimestamp":1767960941,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Inc (LBRX) has an average rating of Buy and mean price target of $44.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LBRX","LB"],"gpt_icon":0},{"id":"2602321369","title":"LB Pharmaceuticals initiated with a Buy at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2602321369","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602321369?lang=en_us&edition=fundamental","pubTime":"2026-01-09 17:30","pubTimestamp":1767951020,"startTime":"0","endTime":"0","summary":"Roth Capital initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $31 price target The company’s LB-102, a Phase 3-ready schizophr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-initiated-with-a-buy-at-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-initiated-with-a-buy-at-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LB","LBRX","BK4213","BK4233","BK4007"],"gpt_icon":0},{"id":"2602534160","title":"LB Pharmaceuticals, Inc. (LBRX) Receives a New Rating from Roth MKM","url":"https://stock-news.laohu8.com/highlight/detail?id=2602534160","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602534160?lang=en_us&edition=fundamental","pubTime":"2026-01-09 13:35","pubTimestamp":1767936919,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals, Inc. received a Buy rating and a $31.00 price target from Roth MKM analyst Boobalan Pachaiyappan today. According to TipRanks, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lb-pharmaceuticals-inc-lbrx-receives-a-new-rating-from-roth-mkm-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lb-pharmaceuticals-inc-lbrx-receives-a-new-rating-from-roth-mkm-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LB","LBRX"],"gpt_icon":0},{"id":"2601894860","title":"Lb Pharmaceuticals Strengthens Leadership Team With Key Appointments in Corporate Affairs and People & Culture","url":"https://stock-news.laohu8.com/highlight/detail?id=2601894860","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601894860?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:00","pubTimestamp":1767700805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA7PBCHK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"gpt_icon":0},{"id":"2601894562","title":"Press Release: LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture","url":"https://stock-news.laohu8.com/highlight/detail?id=2601894562","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601894562?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:00","pubTimestamp":1767700800,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan. 06, 2026  -- LB Pharmaceuticals, Inc  , a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointments of Ellen Rose as Senior Vice President, Corporate Affairs and Lindsay Beaupre as Senior Vice President, People and Culture.Ms. Beaupre is a strategic and results-driven People and Culture executive with an extensive track record in the biotech and financial services sectors, driving organizational effectiveness, leadership capability, and cultural clarity. She partners closely with executive teams to build high-performing organizations during periods of growth and change. Most recently Ms. Beaupre was the Chief Administrative Officer at Lyndra Therapeutics, where she led enterprise-wide people and operational initiatives. Earlier in her career she held senior people leadership roles at prominent biotech companies such as Vertex Pharmaceuticals and Immunoge","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4233","BK4007","LB","LBRX","BK4120","TISI","BK4213"],"gpt_icon":0},{"id":"2592118076","title":"Aktis Oncology files for US IPO as biotech listings rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=2592118076","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592118076?lang=en_us&edition=fundamental","pubTime":"2025-12-20 06:45","pubTimestamp":1766184347,"startTime":"0","endTime":"0","summary":"Aktis Oncology files for US IPO as biotech listings reboundDec 19 (Reuters) - Aktis Oncology filed for an initial public offering in the United States on Friday, as stock market listings from the biot","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nL6N3XP14T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4452.SGD","LU0980610538.SGD","IE00BFXG1179.USD","LU1668664300.SGD","LU1363072403.SGD","LU0321505439.SGD","LU0306806265.USD","LU0320765646.SGD","LU1162221912.USD","LU0203345920.USD","IE00BBT3K403.USD","LU0203347892.USD","BAC","LU0256863811.USD","LU0640476718.USD","LU0170899867.USD","LU0310800965.SGD","LU0256863902.USD","LU0417517546.SGD","BK4559","LU1883839398.USD","LU0052756011.USD","MNSH","BK4207","BK4504","LU2265009873.SGD","IE00BZ1G4Q59.USD","BK4585","BK4588","LU0208291251.USD","LU0971096721.USD","LU0787776722.HKD","LU1366192091.USD","IE0002270589.USD","OWL","LU1880398554.USD","LU1496350171.SGD","LU0149725797.USD","LU0477156797.USD","LU1069347547.HKD","MPLT","LU1894683264.USD","LU2133065610.SGD","LU2129689431.USD","BK4139","LU0306807586.USD","LBRX","EVMN","LU0868494617.USD","LU0130518102.USD"],"gpt_icon":0},{"id":"2590555921","title":"LB Pharmaceuticals Grants Chief Commercial Officer Stock Options Valued at $21.36 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2590555921","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590555921?lang=en_us&edition=fundamental","pubTime":"2025-12-11 06:04","pubTimestamp":1765404252,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Inc. has granted Kaya Pai Panandiker, the new Chief Commercial Officer, an option to purchase 195,000 shares of the company's common stock. The stock option has a ten-year term with an exercise price of $21.36 per share, matching the closing price on the grant date. The option will vest over four years, with 25% vesting on the first anniversary of the grant and the remaining shares vesting in equal monthly installments thereafter, contingent on continued service.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL52vCgm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014005.SGD","LU2210150020.SGD","NDAQ","LU0314104364.USD","BK4585","BK4588","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014039.USD","IE00BKPKM429.USD","BK4112","SG9999014021.USD","LBRX","IE00BGHQF748.EUR","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4007"],"gpt_icon":0},{"id":"2590555923","title":"Lb Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590555923","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590555923?lang=en_us&edition=fundamental","pubTime":"2025-12-11 06:04","pubTimestamp":1765404243,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA3WM71K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"gpt_icon":0},{"id":"2590555115","title":"Press Release: LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590555115","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590555115?lang=en_us&edition=fundamental","pubTime":"2025-12-11 06:04","pubTimestamp":1765404240,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec. 10, 2025  -- LB Pharmaceuticals Inc   today announced that it has granted to Kaya Pai Panandiker, the new Chief Commercial Officer of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on December 10, 2025, pursuant to the \"inducement grant\" exception provided under Nasdaq Listing Rule 5635 as an inducement material to Ms. Pai Panandiker entering into employment with LB Pharmaceuticals.Ms. Pai Panandiker received an option to purchase 195,000 shares of LB Pharmaceuticals' common stock. The option carries a ten-year term and an exercise price per share equal to $21.36, which was the closing price of LB Pharmaceuticals' common stock on the date of grant, and vests over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48  of the shares vesting monthly thereafter, subject to c","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","BK4007","LBRX","BK4233","LB","BK4213"],"gpt_icon":0},{"id":"2590349546","title":"LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices","url":"https://stock-news.laohu8.com/highlight/detail?id=2590349546","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590349546?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:00","pubTimestamp":1765285200,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  09, 2025  (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the Company has been included in the Russell 2000Index and t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202281/0/en/LB-Pharmaceuticals-Added-to-the-Russell-2000-and-Russell-3000-Indices.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4233","LB","BK4007","LBRX","BK4213"],"gpt_icon":0},{"id":"2585462394","title":"Lb Pharmaceuticals Announces Presentation at the Piper Sandler 37TH Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462394","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462394?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:00","pubTimestamp":1763989205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUA9BCVXH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PIPR","LBRX","BK4127"],"gpt_icon":0},{"id":"2584962506","title":"LB Pharmaceuticals Inc. Files Initial Beneficial Ownership Statement for Chief Commercial Officer Kaya Kamlesh Pai Panandiker","url":"https://stock-news.laohu8.com/highlight/detail?id=2584962506","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584962506?lang=en_us&edition=fundamental","pubTime":"2025-11-19 07:58","pubTimestamp":1763510306,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Inc. Files Initial Beneficial Ownership Statement for Chief Commercial Officer Kaya Kamlesh Pai Panandiker. LB Pharmaceuticals Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Kaya Kamlesh Pai Panandiker as the beneficial owner, serving as Chief Commercial Officer of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 18, 2025, and is solely responsib","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL6MvGjT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX"],"gpt_icon":0},{"id":"2583989715","title":"LB Pharmaceuticals Expands One Penn Plaza Lease with Additional 4,634 Square Feet","url":"https://stock-news.laohu8.com/highlight/detail?id=2583989715","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583989715?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:15","pubTimestamp":1763039757,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals Inc. has entered into a First Amendment of Lease with One Penn Plaza LLC, amending its existing lease agreement dated May 20, 2024. The amendment provides for the lease of an additional 4,634 rentable square feet on the 10th floor at One Penn Plaza, New York. The lease term is scheduled to expire on March 31, 2032. The landlord will endeavor to deliver the expansion premises by July 1, 2026. Upon delivery, the fixed rent for the expansion premises will be $430,962 per year for the first three years, increasing to $477,302 per year starting on the third anniversary of the commencement date. A fixed rent abatement will apply for the first 150 days following delivery, subject to the terms of the amendment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDLc77LdL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4223","BK4194","BK4007","LBRX","BK4588","BK4585","VNO"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":62,"code":"91000000","status":"200"}]}}